1. Effects of disease-modifying drugs in multiple sclerosis on the gut microbiome
   Мadina А. Omarova et al, 2024, Journal of Clinical Practice CrossRef
2. Signaling through the S1P−S1PR Axis in the Gut, the Immune and the Central Nervous System in Multiple Sclerosis: Implication for Pathogenesis and Treatment
   Simela Chatzikonstantinou et al, 2021, Cells CrossRef
3. Unveiling the biological role of sphingosine-1-phosphate receptor modulators in inflammatory bowel diseases
   Evanthia Tourkochristou et al, 2023, World Journal of Gastroenterology CrossRef
4. The Role of the Lymphatic System in the Pathogenesis and Treatment of Inflammatory Bowel Disease
   Dimitrios Nikolakis et al, 2022, International Journal of Molecular Sciences CrossRef
5. Knockout of Ceramide Kinase Aggravates Pathological and Lethal Responses in Mice with Experimental Colitis
   Satomi Suzuki et al, 2018, Biological and Pharmaceutical Bulletin CrossRef
6. Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives
   Fabrizio Calapai et al, 2022, Evidence-Based Complementary and Alternative Medicine CrossRef
7. Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models
   Qian Han et al, 2020, Journal of Natural Products CrossRef
8. Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations
   Manar Alyamani et al, 2023, Frontiers in Immunology CrossRef
9. The role of sphingosine-1-phosphate in the gut mucosal microenvironment and inflammatory bowel diseases
   Fei Zou et al, 2023, Frontiers in Physiology CrossRef
10. Frontiers in Drug Research and Development for Inflammatory Bowel Disease
    Diego Currò et al, 2017, Frontiers in Pharmacology CrossRef
11. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
    Tamara Pérez-Jeldres et al, 2019, Frontiers in Pharmacology CrossRef